Gennex Laboratories (531739) Stock Overview
Manufactures and sells bulk drugs, intermediates, and biotech products. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
531739 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Gennex Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹12.94 |
| 52 Week High | ₹19.00 |
| 52 Week Low | ₹10.84 |
| Beta | 0.50 |
| 1 Month Change | -17.89% |
| 3 Month Change | 2.78% |
| 1 Year Change | -28.07% |
| 3 Year Change | 110.41% |
| 5 Year Change | 182.53% |
| Change since IPO | 978.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| 531739 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 0.2% | -0.4% | -0.3% |
| 1Y | -28.1% | -2.2% | -2.3% |
Return vs Industry: 531739 underperformed the Indian Pharmaceuticals industry which returned -2.2% over the past year.
Return vs Market: 531739 underperformed the Indian Market which returned -2.3% over the past year.
Price Volatility
| 531739 volatility | |
|---|---|
| 531739 Average Weekly Movement | 7.9% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IN Market | 8.6% |
| 10% least volatile stocks in IN Market | 3.1% |
Stable Share Price: 531739's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: 531739's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 115 | Arihant Baid | www.gennexlab.com |
Gennex Laboratories Limited manufactures and sells bulk drugs, intermediates, and biotech products. The company offers Guaifenesin, an expectorant used as a mucolyte; Methocarbamol for skeletal muscle relaxant; Fexofenadine Hcl for treating antihistamines; Phenazopyridine Hcl for the treatment of urinary tract analgesic; Fluconazole for antifungals; Melitracen Hcl for treating tricyclic antidepressant; Sertraline Hcl, a selective serotonin reuptake inhibitor; Chlorphenesin and Mephenesin for muscle relaxant; and Allopurinol, a xanthine oxidase inhibitor. It has operations in India, Algeria, Bangladesh, Barzil, Bolivia, Colombia, the Czech Republic, Egypt, El Salvador, Germany, Guatemala City, Mexico, Peru, Spain, Turkey, Thailand, the United Arab Emirates, and Vietnam.
Gennex Laboratories Limited Fundamentals Summary
| 531739 fundamental statistics | |
|---|---|
| Market cap | ₹2.94b |
| Earnings (TTM) | ₹185.52m |
| Revenue (TTM) | ₹1.49b |
Is 531739 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 531739 income statement (TTM) | |
|---|---|
| Revenue | ₹1.49b |
| Cost of Revenue | ₹1.08b |
| Gross Profit | ₹411.37m |
| Other Expenses | ₹225.85m |
| Earnings | ₹185.52m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.82 |
| Gross Margin | 27.53% |
| Net Profit Margin | 12.41% |
| Debt/Equity Ratio | 39.8% |
How did 531739 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/15 01:35 |
| End of Day Share Price | 2025/12/15 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Gennex Laboratories Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.